Vertex Pharmaceuticals’ acquisition of Crinetics Pharmaceuticals values the company at about $10 billion. Crinetics’s Palsonify could become a new standard of care therapy for acromegaly and the biotech also brings other drugs in various stages of development for endocrine disorders, a new therapeutic area for Vertex.
The post Vertex Pharma’s Growth Strategy Leads to Its Biggest-Ever M&A Deal appeared first on MedCity News.
